NCM · Financial Statements

Barinthus Biotherapeutics plc (BRNS) Financial Statements

$0.67 NCM: BRNS

Barinthus Biotherapeutics plc most recently reported annual revenue of $0, a net loss of $66.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Barinthus Biotherapeutics plc: Revenue fell from $5.0M in 2020 to $0 in 2025, a change of -100.0% over 5 years; net profit was positive in 1 of 6 reported years; operating margin moved from -416.0% to -454.0%, a shift of -38.0 percentage points; the most recent year shows a net loss of $66.0M.

Income Statement — 6 Years (USD millions)

Metric202020212022202320242025
Revenue$5.0M$0$45.0M$1.0M$15.0M$0
Operating Expenses$25.0M$45.0M$49.0M$85.0M$83.0M$71.0M
Operating Profit$-20.0M$-45.0M$-4.0M$-84.0M$-68.0M$-71.0M
Operating Margin-416.0%-16874.0%-9.0%-10463.0%-454.0%0.0%
Other Income$2.0M$-6.0M$5.0M$7.0M$7.0M$4.0M
Interest$4.0M$3.0M$0$0$0$0
Depreciation$0$1.0M$4.0M$5.0M$6.0M$6.0M
Profit Before Tax$-18.0M$-51.0M$1.0M$-77.0M$-61.0M$-67.0M
Tax—$0$-526.0M$4.0M$0$0
Net Profit$-18.0M$-51.0M$5.0M$-73.0M$-61.0M$-66.0M
EPS$-2.24$-1.96$0.14$-1.91$-1.55$-1.64
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

MetricMar '23Jun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Mar '26
Revenue$0$0$0$0$0$0$15.0M$0——$0—
Operating Expenses$22.0M$27.0M$16.0M$20.0M$17.0M$18.0M$24.0M$23.0M——$15.0M—
Operating Profit$-21.0M$-26.0M$-16.0M$-20.0M$-17.0M$-18.0M$-9.0M$-23.0M$-21.0M$-23.0M$-15.0M$-6.0M
Operating Margin-4591.0%-7885.0%0.0%0.0%0.0%0.0%-63.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-19.0M$-25.0M$-15.0M$-18.0M$-16.0M$-17.0M$-8.0M$-21.0M$-20.0M$-21.0M$-15.0M$-6.0M
Tax$3.0M$5.0M$4.0M$5.0M$0$0$0$0$0$0$0$0
Net Profit$-18.0M$-24.0M$-14.0M$-17.0M$-16.0M$-17.0M$-8.0M$-21.0M$-20.0M$-21.0M$-15.0M$-6.0M
EPS$-0.48$-0.62$-0.37$-0.45$-0.40$-0.43$-0.21$-0.51$-0.49$-0.52$-0.36$-0.14

Over the 6 years reported for Barinthus Biotherapeutics plc, cash stood at $70.0M in the latest year, shareholders' equity was $394.0M, current assets covered current liabilities 7.80 times.

Balance Sheet — 6 Years (USD millions)

Metric202020212022202320242025
Total Assets$51.0M$281.0M$270.0M$215.0M$160.0M$98.0M
Current Assets$48.0M$227.0M$213.0M$157.0M$126.0M$78.0M
Cash$43.0M$214.0M$194.0M$142.0M$111.0M$70.0M
Inventory——————
Receivables$1.0M$0$0$0$0$0
Fixed Assets$1.0M$2.0M$8.0M$12.0M$7.0M$4.0M
Capital Work in Progress$0$0$0$0$0$0
Investments——————
Other Assets—$13.0M$12.0M$12.0M$1.0M$1.0M
Total Liabilities$54.0M$28.0M$27.0M$28.0M$30.0M$24.0M
Current Liabilities$8.0M$11.0M$12.0M$13.0M$16.0M$10.0M
Borrowings—$0$0$0$0$0
Other Liabilities$54.0M$28.0M$27.0M$27.0M$30.0M$24.0M
Equity$22.0M$369.0M$380.0M$387.0M$393.0M$394.0M
Reserves—$252.0M$243.0M$187.0M$130.0M$74.0M

For Barinthus Biotherapeutics plc, operating cash flow was positive in 0 of 6 reported years; free cash flow in the latest year was negative at $48.0M; free cash flow was positive in 0 of 6 years.

Cash Flow Statement — 6 Years (USD millions)

Metric202020212022202320242025
Operating Cash Flow$-11.0M$-33.0M$-14.0M$-51.0M$-29.0M$-48.0M
Investing Cash Flow$0$-13.0M$-6.0M$-5.0M$-1.0M$0
Financing Cash Flow$41.0M$223.0M$0$2.0M$2.0M$0
Net Cash Flow$30.0M$177.0M$-20.0M$-54.0M$-28.0M$-48.0M
Free Cash Flow$-11.0M$-34.0M$-21.0M$-56.0M$-30.0M$-48.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio7.80
Interest Coverage—
Return 1Y-52.82%
Return 3Y-70.35%
Return 5Y—

Barinthus Biotherapeutics plc (BRNS) financials — frequently asked questions

What is Barinthus Biotherapeutics plc's annual revenue?

Barinthus Biotherapeutics plc (BRNS) reported annual revenue of $0 in its most recent fiscal year.

What is Barinthus Biotherapeutics plc's net profit?

Barinthus Biotherapeutics plc (BRNS) reported a net loss of $66.0M in its most recent fiscal year.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
BRNS Overview BRNS Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.